Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2024
0mins
Source: Newsfilter
IMM-1-104 Development: Immuneering Corporation's IMM-1-104 has received Fast Track designation from the FDA for treating NRAS-mutant melanoma patients who have progressed on or are intolerant to existing immune checkpoint inhibitors, with promising Phase 1 trial results indicating better tolerance compared to current MEK inhibitors.
Clinical Trials and Future Prospects: The drug is currently being evaluated in a Phase 2a clinical trial, and the company aims to develop universal-RAS therapies that selectively target cancer cells while minimizing effects on healthy cells.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on IMRX
Wall Street analysts forecast IMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRX is 14.50 USD with a low forecast of 11.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.000
Low
11.00
Averages
14.50
High
20.00
Current: 5.000
Low
11.00
Averages
14.50
High
20.00
About IMRX
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Rise on Venezuela Action; Chevron Shares Up 5.8%
- Market Rally: U.S. equities wrapped the first full trading week of 2026 on a strong note, with both the S&P 500 and Dow Jones Industrial Average reaching new record highs, reflecting investor optimism about economic recovery.
- Energy Stocks Surge: Following U.S. military actions in Venezuela, Chevron shares rose approximately 5.8%, as investors expressed optimism about potential access to the country's oil resources, highlighting the direct impact of geopolitical events on market performance.
- Defense Stocks Rise: Anticipation of a significantly larger Pentagon budget in 2027 led to substantial gains for defense contractors, indicating a strong market focus on defense spending and confidence in future growth prospects.
- Mixed Economic Data: The December jobs report revealed slower-than-expected payroll growth but a declining unemployment rate, easing investor concerns about labor market stress and supporting the narrative that the Fed may hold rates steady in the near term.
Continue Reading
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction
- Jobless Claims Increase: U.S. initial jobless claims rose by 8,000 to 208,000 for the week ending January 3, slightly below market expectations of 210,000, indicating ongoing labor market pressures that could affect economic recovery confidence.
- Productivity Gains: Nonfarm business sector labor productivity increased by 4.9% in Q3, following a revised 4.1% gain in the previous quarter, suggesting progress in efficiency improvements that may support future economic growth.
- Unit Labor Costs Decline: Unit labor costs in the nonfarm business sector fell by 1.9% in Q3, contrary to market expectations of a 1.0% increase, indicating successful cost control by businesses that could bolster profit margins.
- Trade Deficit Shrinks: The U.S. trade deficit narrowed to $29.4 billion in October, the smallest gap since June 2009, significantly lower than the revised $48.1 billion deficit in September, reflecting improved international trade conditions that may contribute to economic stability.
Continue Reading